CEL-SCI starts head, neck cancer drug Phase III trial in Poland
The company expects to recruit around 85 patients in five clinical trial centers in the Poland. The Phase III trial intends to establish whether Multikine administered before current
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.